Appears on
Articles2
A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use soansm01 Wed, 06/10/2026 - 02:23 Nurtec® ODT Rimegepant PHASE IV Tue, 10/18/2022 - 12:00 Tue, 06/10/2025 - 12:00 NCT05509400 C4951004 (BHV3000-406) Public Disclosure Synopsis.pdf (169.8
0
Pfizer1mo agoAn Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin
An Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin soansm01 Fri, 06/26/2026 - 04:52 PF-07220060 PF-07220060 PHASE II Thu, 07/11/2024 - 12:00 Thu, 07/10/202
0
Pfizer14d ago